Platelet angiotensin II receptors in pregnancy

Pawlak, M.; Macdonald, Graham

doi:10.1042/cs0830737

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The platelet angiotensin receptors were described a decade ago [100,101] and the platelet model has been extensively used in many in vitro and ex vivo studies [102,103]. Previous findings suggest that ARBs (including losartan and valsartan) exhibits potent antiplatelet properties [104][105][106][107][108][109].…”

Section: The Pleiotropic Action Of Antihyperten-sive Drugs: Effects Omentioning

confidence: 99%

Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications

Ferroni¹,

Guadagni

2008

CHDDT

View full text Add to dashboard Cite

Soluble CD40 ligand (sCD40L) is involved in the pathogenesis of risk factor-related vascular damage and has been regarded as a molecular link between inflammation, thrombosis and angiogenesis. Given the increasingly recognized theory that hypertension is in part an inflammatory disorder, the contribution of CD40/CD40L dyad is becoming one of the outstanding puzzles in the pathophysiology of hypertension. CD40/CD40L signaling appears, in fact, like a versatile pathway that vehicles information within vascular cells. Several distinct lines of investigation in the context of hypertension dealing with low-grade inflammation are now merging, with CD40/CD40L system as the missing link. As an example, recent data suggest that the vasoactive peptide angiotensin II promotes and augments the inflammatory activation induced by CD40/CD40L ligation in human vascular cells. Accordingly, sCD40L levels are elevated in hypertensive patients and might discriminate hypertensive patients at a high risk of cardiovascular events. This review will summarize the present understanding of the contribution of sCD40L to inflammation, thrombosis and neoangiogenesis in hypertension. Furthermore, given the well established effects that antihypertensive drugs exert on the vasculature beyond blood pressure lowering (pleiotropic effects), we will also discuss the effects of antihypertensive treatment on these phenomena.

show abstract

Section: The Pleiotropic Action Of Antihyperten-sive Drugs: Effects Omentioning

confidence: 99%

Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications

Ferroni¹,

Guadagni

2008

CHDDT

View full text Add to dashboard Cite

show abstract

“…Hypertension leads to endothelial dysfunction, enhanced coagulation, depressed fibrinolysis and platelet activation promoting the prothrombotic state (24). The platelet angiotensin receptors were described a decade ago (25,26), and the platelet model has been extensively used in many of the in vitro and ex vivo studies (27,28). Activation of the platelet angiotensin receptors potentially could contribute to further progression of thrombotic events.…”

Section: Angiotensin Receptor Blockersmentioning

confidence: 99%

Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors

Malinin¹,

Ong²,

Макаров³

et al. 2006

International Journal of Clinical Practice

View full text Add to dashboard Cite

Aspirin, dipyridamole, cilostazol, thienopyridines and glycoprotein IIb/IIIa inhibitors represent the classical examples of the established antiplatelet agents commonly used for the secondary prevention in patients after vascular events. Obviously, the era of expanding antiplatelet regimens and indications may require new agents as the substitutes, or additions to the available strategies. However, recent results of the majority of antiplatelet trials strongly suggest boarder line advantages in clinical outcomes, and higher associated bleeding risks with the novel antiplatelet agents or/and regimens. Moreover, unexpected failures, such as lack of efficacy of clopidogrel and aspirin combination for ischaemic stroke prevention (MATCH), or use of the same antiplatelet regimen for the primary vascular prevention (CHARISMA) raise legitimate concerns that the concept 'the more the better' may not be valid. Broad use of statins, angiotensin receptor blockers and selective serotonin reuptake inhibitors may be in part responsible for the lack of impressive results with the antiplatelet therapy because each of these drug classes per se inhibits platelets. In this review, we discuss the available evidence and potential clinical significance of these findings.

show abstract

Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial

Serebruany

Pokov

Malinin

et al. 2006

American Heart Journal

View full text Add to dashboard Cite

Platelet angiotensin II receptors in pregnancy

Cited by 3 publications

References 0 publications

Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications

Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications

Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors

Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial

Contact Info

Product

Resources

About